AORT vs EW
AORT: Artivion is a specialist medical device company delivering advanced surgical solutions, including stent grafts, mechanical heart valves, and tissue processing, for the treatment of aortic disease. EW: Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring.
Side-by-side fundamentals
| Metric | AORT | EW | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $21.21 | $84.24 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $1.0B | $48.6B | |
| P/E as of 2026-10-08 | 88.63 | 48.74 | EW lower |
| Net margin FY2025, SEC XBRL | +2.2% | +17.7% | EW higher |
| Gross margin FY2025, SEC XBRL | +64.4% | +78.0% | EW higher |
| Operating margin FY2025, SEC XBRL | +7.6% | +20.8% | EW higher |
| ROE FY2025, SEC XBRL | +2.2% | +10.4% | EW higher |
| ROA FY2025, SEC XBRL | +1.1% | +7.8% | EW higher |
| Debt / equity as of 2026-09-03 | 0.49 | 0.06 | EW lower |
| Revenue growth (YoY) as of 2026-09-03 | +17.6% | +14.6% | AORT higher |
| Revenue CAGR (3y) SEC XBRL | +12.0% | +10.8% | AORT higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.59 | 0.55 | |
| 1-year return as of 2026-10-08 close | -48.3% | +11.2% | EW higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.